Your AI-Trained Oncology Knowledge Connection!

Advancements in Treatment Management Strategies for EGFR-Mutated NSCLC: Insights from Experts at The University of California Irvine : Episode 7

Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

October 30, 2023

By Misako Nagasaka, MD, PhD
Kristen Neumann, DNP, FNP-C

Opinion

Video

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Now Viewing

EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP: 9.EGFR Mutations in Patients With NSCLC

EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment

EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!